Analyst Price Target is $36.00
▲ +87.70% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Summit Therapeutics in the last 3 months. The average price target is $36.00, with a high forecast of $45.00 and a low forecast of $23.00. The average price target represents a 87.70% upside from the last price of $19.18.
Current Consensus is
Moderate Buy
The current consensus among 3 contributing investment analysts is to moderate buy stock in Summit Therapeutics. This Moderate Buy consensus rating has held steady for over two years.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Read More
